
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About
Alvotech Warrant (ALVOW)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/26/2025: ALVOW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $
1 Year Target Price $
0 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 33.63% | Avg. Invested days 37 | Today’s Advisory WEAK BUY |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.19 | 52 Weeks Range 1.02 - 4.99 | Updated Date 05/16/2025 |
52 Weeks Range 1.02 - 4.99 | Updated Date 05/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16.42% | Operating Margin (TTM) 7.97% |
Management Effectiveness
Return on Assets (TTM) 7.02% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 100126591 |
Shares Outstanding - | Shares Floating 100126591 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Alvotech Warrant
Company Overview
History and Background
Alvotech is a biopharmaceutical company focused on the development and manufacture of biosimilar medicines. The warrant provides the holder the right to purchase shares of Alvotech common stock under specific terms.
Core Business Areas
- Biosimilar Development: Alvotech focuses on developing biosimilars for a range of therapeutic areas, targeting complex molecules and high-value biological products.
- Manufacturing: The company has advanced manufacturing capabilities for producing biosimilars at scale.
- Commercialization: Alvotech partners with other pharmaceutical companies to commercialize its biosimilars globally.
Leadership and Structure
Alvotech is led by a team with experience in biosimilar development, manufacturing, and commercialization. The organizational structure includes departments for research and development, manufacturing, quality control, and commercial operations.
Top Products and Market Share
Key Offerings
- AVT02 (adalimumab biosimilar): A biosimilar of Humira (adalimumab) used to treat autoimmune diseases. Competitors include Amgen (Amjevita), Sandoz (Hyrimoz), and other adalimumab biosimilars. Market share data is variable depending on region and launch timing but this is a lead product. Revenue from AVT02 is a significant portion of Alvotech's total revenue, though specific figures are proprietary.
- AVT04 (ustekinumab biosimilar): A biosimilar of Stelara (ustekinumab) used to treat psoriasis, Crohn's disease, and ulcerative colitis. Competitors will include biosimilars developed by other pharmaceutical companies such as Biocon and possibly Amgen. Market share will depend on launch timing and regulatory approvals. Currently in development.
Market Dynamics
Industry Overview
The biosimilar market is growing rapidly as patents on many blockbuster biologics expire. This creates opportunities for companies like Alvotech to develop and commercialize more affordable versions of these drugs.
Positioning
Alvotech is positioned as a key player in the biosimilar market with a focus on complex molecules and a global commercialization strategy. Its competitive advantage lies in its manufacturing capabilities and partnerships with established pharmaceutical companies.
Total Addressable Market (TAM)
The global biosimilars market is expected to reach hundreds of billions of dollars by the end of the decade. Alvotech is positioned to capture a significant share of this market with its portfolio of biosimilars targeting high-value biologics. TAM estimates range from $400-$700 billion by 2030.
Upturn SWOT Analysis
Strengths
- Strong pipeline of biosimilar candidates
- Advanced manufacturing capabilities
- Strategic partnerships for commercialization
- Focus on complex molecules
Weaknesses
- Reliance on partnerships for commercialization
- Regulatory hurdles for biosimilar approvals
- Intense competition in the biosimilar market
- Relatively smaller size compared to major pharmaceutical companies
Opportunities
- Expanding biosimilar market globally
- Patent expirations of blockbuster biologics
- Growing demand for affordable medicines
- Potential for new partnerships and collaborations
Threats
- Regulatory challenges and delays
- Price erosion due to competition
- Patent litigation from originator companies
- Biosimilar adoption barriers
Competitors and Market Share
Key Competitors
- AMGN
- PFE
- VTRS
Competitive Landscape
Alvotech's competitiveness hinges on its biosimilar pipeline, manufacturing efficiency, and market access strategies against larger, more established pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth depends on past performance metrics, as well as successful biosimilar commercialization.
Future Projections: Future projections would depend on successful drug approvals and partnerships.
Recent Initiatives: Recent initiatives include new partnerships and commercialization agreements.
Summary
Alvotech warrants are inherently speculative because they are only valuable if Alvotech's stock rises above the strike price before the warrant expires. Success depends on successful drug development, regulatory approvals, and commercialization partnerships. The biosimilar market is competitive, and Alvotech faces threats from larger pharmaceutical companies and potential delays. However, the warrants offer potential for high returns if Alvotech can successfully execute its growth strategy.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings
- Company press releases
- Industry reports
- Analyst reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alvotech Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-06-16 | CEO, Founder & Executive Chairman Mr. Robert Wessman | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1012 | Website https://www.alvotech.com |
Full time employees 1012 | Website https://www.alvotech.com |
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.